We performed a phase I trial of recombinant human interleukin-11 (rhlL-11) in women with breast cancer. Cohorts of three t o five women were accrued t o five dosage levels of rhlL-11 (10. 25, 50, 75, and 100 pglkgld). rhlL-11 alone was administered by a daily subcutaneous injection for 14 days during a 28-day prechemotherapy "cycle 0." Patients (pts) subsequently received up t o four 28-day cycles of cyclophosphamide (1,500 mg/m*) and doxorubicin (60 mg/m2) chemotherapy followed by rhlL-11 at their assigned dose (days 3 through 14). Sixteen pts (13 stage IV, 3 stage 111B) were accrued t o this study. Median age was 53 years and median Eastern Cooperative Oncology Group Performance Status was 0. A grade 3 neurologic event was seen in 1 pt at 100 pg/kg. Because of the degree of grade 2 constitutional symptoms (myalgias/arthralgias and fatigue) at 75 pglkg, dose escalation was stopped and 75 pg/kg was the maximally tolerated dose. No other grade 3 or 4 adverse events related t o rhlL-11 were seen. The HROMBOCYTOPENIA has become an increasing T problem for cancer patients receiving chemotherapy.
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Because the use of the myeloid colony-stimulating factors (CSFs) has reduced the incidence of febrile neutropenia after standard-dose chemotherapy, the administration of more dose-intensive chemotherapy regimens has been pursued. ' As a result, greater degrees of acute and prolonged thrombocytopenia are increasingly being observed. This has resulted in an increased utilization of platelet transfusions with the inherent increased risk of transfusion-related infectious complications. In addition, the quality of life of those patients requiring frequent blood counts and transfusions is impaired. Although the use of reinfused peripheral blood (PB) progenitor cells has reduced the degree of thrombocytopenia associated with high-dose chemotherapy, this technology is cumbersome and costly. No currently available hematopoietic growth factor routinely reduces the degree of thrombocytopenia secondary to cytotoxic chemotherapy in a manner similar to that of the myeloid CSFs.
Interleukin-1 1 (IL-1 1) is a pleiotropic hematopoietic growth factor initially detected in the conditioned medium derived from the immortalized primate bone marrow (BM) stromal cell line PU-34. ' The activity of this agent was characterized by its stimulation of the proliferation of the IL-6-dependent plasmacytoma cell line, TI 165. This effect was not eliminated by the addition of anti-IL-6 antibodies, showing that this was a unique factor. The human homologue of the IL-11 gene was isolated from a lung fibroblast cell line and encoded a 19-kD protein comprised of 178 amino acids. This gene is located on chromosome 19.'
In vitro, IL-11 synergizes with other hematopoietic growth factors (eg, IL-3 and c-kit ligand) promoting the proliferation of various classes of hematopoietic progenitor cells committed to a variety of lineage^.^.^ As a single agent, IL-11 induces the maturation of early megakaryocytes by increasing megakaryocyte size and ploidy. 6 In preclinical in vivo models, IL-1 1 stimulates platelet production in normal animals, including mice and nonhuman primates. This effect is doseadministration of rhlL-11 was not associated with fever. Reversible grade 2 fatigue and myalgiaslarthralgias were seen in all pts at 75 pglkg. Weight gain of 3% t o 590 associated with edema was seen at doses >10 pg/kg but a capillary leak syndrome was not seen. rhlL-11 alone was associated with a mean 7690, 93%. 108%. and 185% increase in platelet counts at doses of 10,25,50, and 75 pg/kg. respectively. No significant changes in leukocytes were seen. A mean 19% decrease in hematocrit was observed. Acutephase proteins increased with treatment at all doses. Compared with patients at the 10 pg/kg dose, patients receiving doses 225 pg/kg experienced less thrombocytopenia in the first t w o cycles of chemotherapy. We conclude that rhlL-11 has thrombopoietic activity at all doses studied, is well tolerated at doses of 10,25, and 50 pg/kg, and at doses 225 pg/kg has the potential t o reduce chemotherapy-induced thrombocytopenia in this model. 0 1996 by The American Society of Hematology. related and is characterized by increases in peripheral platelet counts, which peak approximately 14 to 21 days after initiation of administrati~n.'.~ Multilineage effects, including increases in reticulocytes and white blood cell (WBC) subsets, have been seen in several of these preclinical models.' After the administration of chemotherapy to mice, IL-1 1 significantly accelerates the multilineage recovery of hematopoies~s .~ When IL-11 is administered in a murine transplant model, it demonstrates similar multilineage effects, accelerating the recovery of platelets, neutrophils, and reticulocytes."
Based on its in vitro and in vivo preclinical thrombopoietic activity, we hypothesized that IL-11, having potential thrombopoietic activity and multilineage hematologic effects, would be an ideal hematopoietic growth factor to diminish the degree of chemotherapy-related thrombocytopenia. Our goal was to assess the safety and biologic properties of the recombinant protein (Neumega rhIL-11 growth factor; rhIL-1 1). In our study, rhIL-11 was administered to women with breast cancer both before and after dose-intensive chemo-3616 GORDON ET AL therapy. We report that rhIL-11 is well tolerated at clinically relevant doses and has thrombopoietic activity in women with normal hematopoiesis. When administered after the administration of dose-intensive chemotherapy, rhIL-1 1 at doses of 25 to 75 p g k g subcutaneously (SC) daily has the ability to attenuate the development of severe thrombocytopenia.
MATERIALS AND METHODS
Parienr eligibility. Women with pathologically confirmed breast cancer that was either locally advanced (stage IIIB) or metastatic (stage 1V) were eligible for the study if they met the following criteria: age 18 years or older; practicing an approved method of birth control with a negative Beta Human Chorionic Gonadotropin (P-HCG) pregnancy test (if appropriate); an Eastern Cooperative Oncology Group (ECOG) performance status of 5 1; at least 4 weeks from prior adjuvant chemotherapy with complete recovery from all toxicity; adequate hepatic and renal function (total bilirubin level 52.0 mg/dL, blood urea nitrogen (BUN) 5 3 0 mg/dL, serum creatinine level 52.0 mg/dL); normal left ventricular ejection fraction (250% on radionuclide ejection fraction [RNEF]); no prior cbemotherapy for metastatic disease; and no clinically significant cardiac or metabolic disease. Patients were required to be seronegative for human immunodeficiency virus and hepatitis B surface antigen.
Patients with a history of thromboembolic phenomena, prior doxorubicin exposure of >250 mg/m2, those who were anticipated to require radiation therapy during the course of the study, had a contraindication to delaying chemotherapy for 4 weeks, or were receiving treatment with corticosteroids, aspirin, nonsteroidal anti-inflammatory agents, or anticoagulant drugs were excluded. We also excluded patients with a documented history of brain metastases or seizures, or other cancer within 5 years of study entry (with the exception of carcinoma in situ of the uterine cervix or surgically cured nonmelanoma skin cancer). Patients were also ineligible if they had received radiation therapy or surgery within 2 weeks before study entry, had undergone prior pelvic irradiation at any time, or were treated with any investigational agent or cytokine within 4 weeks of study entry. All patients were required to give written informed consent, and the protocol was approved by the Institutional Review Board of the Indiana University School of Medicine.
Study medication. Escherichia coli-derived, nonglycosylated rhIL-11 (Neumega rhIL-11 growth factor) was provided by Genetics Institute (Cambridge, MA). Vials containing 5 mg/mL of rhIL-ll in 1 mL of USP Sterile water for injection were used. Vials were used only once and then discarded. The specific activity of the rhIL-I 1 was determined by a bioassay on the basis of [3H]-thymidine incorporation in a responsive cell line and was >0.6 X IO6 U/mg. The study agent contained less than 1 ng of endotoxin by Limulus amoebocyte lysate assay Cyclophosphamide, doxorubicin, and Neupogen (Amgen Inc, Thousand Oaks, CA) (granulocyte colony-stimulating factor [G-CSF]) were obtained commercially.
The study schema is shown in Fig 1. In this openlabel, nonrandomized phase I trial, 16 patients were enrolled between December 1992 and December 1993. Cohorts of three to five patients were accrued to each of four planned dose levels of rhIL-11 including 10, 25, 50, and 75 pg/kg/d. rbIL-11 was administered as a daily subcutaneous injection for 14 days followed by a 14-day washout period during a 28-day prechemotherapy safety period termed cycle 0. Patients were observed for 6 hours in the General Clinical Research Center at Indiana University Medical Center after each of the first three doses of rhIL-11 and continued to be treated as outpatients thereafter.
After completion of cycle 0, patients received up to four monthly cycles of chemotherapy consisting of cyclophosphamide 1,500 mg/ Study design. m2 and doxorubicin 60 mg/m2 on the first day of each 28-day cycle. All patients received rhIL-I1 at their assigned dose for 12 days (days 3 through 14) following the administration of chemotherapy. Any patient who experienced severe neutropenia defined as a febrile neutropenic event or an absolute neutrophil count 5500 cells/pL for more than 5 days during cycles 1 or 2 were eligible to receive Neupogen at a dose of 5 pgkgld administered SC from day 3 through neutrophil recovery (absolute neutrophil count 22,000 cells/pL for 3 days) in cycles 3 and 4. There was no intrapatient dose escalation allowed. If at any time the platelet count increased to greater than 600,00O/pL during rhIL-l 1 administration, rhIL-11 was distontinued during that cycle of therapy.
Dose escalation was based on adverse events seen in cycle 0 only and was allowed if none of the three patients at a given dose experienced grade 3 or greater adverse events in the first 14 days of IL-I 1 therapy. If one of the three patients experienced a serious adverse event, an additional two patients were added to that cohort. Dose-limiting toxicity (DLT) was defined as the dose which resulted in two or more patients with grade 3 or greater toxicity. The maximally tolerated dose (MTD) was defined as the dose level immediately below that which resulted in DLT. An additional three patients were allowed to be accrued to either the MTD or, in the absence of establishing an MTD, to a safe, biologically active dose. These additional patients did not receive rhIL-11 during cycle 0, and were treated only in cycles 1 through 4 of the study. Patients experiencing grade 3 or greater toxicity were removed from the study. All toxicities were graded according to the World Health Organization (WHO) common toxicity criteria."
All patients underwent a thorough physical examination including vital signs and ECOG performance status before enrollment on the study. This evaluation was repeated at intervals throughout the study. An RNEF (MUGA scan) was performed before Evaluations.
For personal use only. enrollment and repeated after the second and fourth cycles of chemotherapy. A chest radiograph and electrocardiogram were obtained at baseline, after the completion of rhIL-11 administration in cycle 0 (day 15, cycle 0) and at the end of cycle 0 (day 28). Complete blood counts including a manual differential count, absolute reticulocyte count, and an automated quantitation of platelet size were obtained at baseline and three times per week during cycles 0 through 4.
Patients who developed platelet counts ~600,000/pL during cycle 0 underwent daily complete blood counts until the platelet count decreased to below this level. Urinalysis, coagulation profiles, serum chemistries, and serum levels of acute phase proteins (C-reactive protein, fibrinogen, and haptoglobin) were performed at baseline and at varying intervals during cycles 0 through 4. BM aspirates and trephine biopsies for morphology, progenitor cell numbers, immunophenotyping, and megakaryocyte ploidy analysis were performed at baseline and after completion of rhIL-11 administration in cycle 0 (day 15, cycle 0).
Serum samples were evaluated for the development of anti-IL-11 antibodies by an enzyme-linked immunoabsorbent assay (ELISA). Serum samples were obtained at baseline, on day 15 of cycle 0, and before the start of each cycle of chemotherapy (cycles 1 through 4) and at the follow-up visit 4 weeks after the end of the last chemotherapy cycle.
Tumor measurements were obtained at baseline, after completion of cycle 0, and after the second and fourth cycles of chemotherapy. Clinical response was evaluated by comparing tumor measurements obtained from radiographic or physical examination findings. Standard Eastern Cooperative Oncology Group breast cancer response criteria were used. Any patient who was found to have progressive disease at any time was removed from the study. Dose-limiting criteria were defined by standard criteria based on the dose-escalation schema outlined above. Analysis of changes in serum chemistries and acute-phase proteins was performed using a two-sided Student's paired t-test. Results of hematologic parameters were reported as mean or median values. When appropriate, 95% confidence intervals were calculated and presented.
Serum anti-ll-ll antibodies.
Clinical response criteria.
Statistical analysis.

RESULTS
Patient characteristics.
Sixteen patients with pathologically confirmed breast cancer (3 stage IIIB, 13 stage IV) were accrued to this phase I trial. Pretreatment characteristics and extent of diseaselprior therapy are shown in Tables 1  and 2 . All 16 were eligible for assessment of safety. Thirteen patients received rhIL-11 during cycle 0: 12 patients were enrolled in cohorts of 3 at the 10, 25, 50, and 75 pgkg dose levels and 1 patient was enrolled at the 100 p g k g dose level.
After the completion of dose escalation, an additional three patients were accrued to the 50 pgkg dose cohort to gain additional information about the effects of rhIL-11 at this dose after chemotherapy. The median age for patients treated on this study was 53 years (range, 26 to 67 years). Median ECOG performance status was 0 (range, 0 to 1). Nine patients had received prior adjuvant chemotherapy, including 4 who received prior radiation therapy (including patient number 008 at the 50 pgkg dose who had previously received lumbar radiotherapy) and 5 who received prior hormonal therapy. Among the remaining patients, 2 had received prior radiotherapy and hormonal therapy, 2 had received prior hormonal therapy only, and 3 had received no prior therapy (all with stage IIIB disease).
Treatment with rhIL-11 was generally well tolerated. All side effects were reported regardless of their presumed relationship to rhIL-11 (Table 3) . When the rhIL-11 alone cycle (cycle 0) is analyzed, the most common side effect is a therapy-related anemia that occurred in 11 of 11 patients who completed this phase of the trial. This anemia (-20% decrease in hematocrit) generally developed within 2 to 3 days of the initiation of IL-11 dosing and resolved over a 1-to 2-week period after completion of IL-11 therapy. Plasma volume studies performed in three patients showed increased plasma volumes (20%, 18%, and 21%) from days 2 to 15. No patient experienced significant blood loss or had any laboratory evidence of hemolysis. These increases in plasma volume are consistent with the development of the anemia.
The other most frequently reported side effects during cycle 0 included constitutional symptoms including arthralgias and myalgias, fatigue, nausea, and headache. Edema of the extremities was seen in all except one patient treated at doses 2 2 5 pgkg and was primarily dependent in nature. The edema typically developed in the second week of rhIL-11 therapy and resolved after completion of the 14 days of treatment. No clinically significant fevers nor capillary leak syndromes were seen in patients receiving rhIL-1 1 during cycle 0. Although the majority of the side effects seen were mild-moderate (grade 1-2), the constitutional symptoms and edema were believed to be dose-related and were more intense at doses 2 5 0 pgkgld. When cycles of IL-11 administered after chemotherapy were evaluated, a similar toxicity profile was observed. No other unexpected adverse events were identified.
Five patients were removed from study for adverse events believed to be possibly or probably related to the study drug ( Table 4) . Only one patient was removed from study during cycle 0 for a severe adverse event (grade 3 or higher). This patient, the first treated at the 100-pgkg dose level, experienced the onset of an expressive aphasia after three doses of rhIL-11. Computed tomographic (CT) scan of the head showed a 1-to 2-cm left Brocha's infarct and rhIL-11 therapy was discontinued. Her platelet count at the time of admission for the event was 220,0001pL and her fibrinogen level was 670 mg/dL. The patient underwent noninvasive doppler evaluation of her carotid arteries which demonstrated no clinically significant vaso-occlusive disease. With continued observation, the patient recovered to her baseline neurologic status. A second patient, with a history of hypertension, treated at the 50 pgkg dose, was removed after ZL-11 safety.
For identification of a 1-to 2-cm intracerebral bleed at the time of the nadir of her blood counts following chemotherapy during cycle 1. This patient was admitted to the hospital with an episode of neutropenic fever and staphylococcal sepsis. Mental status changes were investigated with a CT scan of the head, which showed a small intracerebral bleed in the setting of chronic hypertensive cerebrovascular disease. The patient was removed from study and recovered completely with no significant sequelae from this event. The third patient, enrolled on the 75-ygkg dose level, withdrew from the study after completion of cycle 1 because of what she perceived as unacceptable constitutional symptoms characterized by fatigue, arthralgias and myalgias, and edema. A final two patients were removed because of indwelling catheter-related complications of infection and thrombosis. Reasons for the removal of additional patients who failed to complete the entire four cycles of chemotherapy included: progression of disease (two patients), change in therapy to BM transplant (one patient), and neutropenic sepsis (one patient). Anti-rhIL-1 1 antibody formation was assessed in all 16 patients. Two subjects were observed to demonstrate an anti-rhIL-11 response that was consistent with antibody formation as a result of product exposure. Of these two, one subject showed a positive response at the follow-up visit only, but had insufficient sample to confirm the authenticity of this titer. The other subject had a relatively low titer 14 days after product exposure, and although this subject did not have a detectable titer at the follow-up visit (26 days postexposure), there was a faint reactivity with the rhIL-11 band when this sample was analyzed by Western immunoblot analysis.
In the first course of therapy IL-11 was administered alone, 4 weeks before chemotherapy, to allow the evaluation of the safety as well as the hematologic and hematopoietic effects of IL-1 1 . Treatment with IL-11 alone was associated with a doserelated increase in platelet counts. Increases of 76%, 93%, 108%, and 185% over baseline values were seen at the IO-, 2 5 , 50-, and 75-pgkg/d dose levels, respectively (Fig  2A through D) . This thrombocytosis was characterized by an initial slight transient decrease in platelets within the first 2 days of IL-I 1 therapy. Subsequently, platelet counts gradually increased to their peak levels over the 2 weeks of treatment. Maximal platelet counts occurred at a median of 18, 19, 16, and 14 days from the initiation of therapy for
Serum anti-rhlL-11 antibodies,
Hematologic effects of IL-1 I during cycle 0. day of treatment the four dose levels, respectively. After completion of rhIL-11 therapy, platelet counts gradually decreased, and all returned to baseline pretreatment values by the initiation of cycle 1. There were no significant changes in the mean platelet volume after IL-11 therapy at any doses studied and platelet aggregometry performed pretreatment and on day 15 demonstrated no consistent evidence of an IL-11 -related effect on platelet function.
IL-11 was associated with a decrease in hematocrit which, at the doses studied in this trial, was not dose-related. This phenomenon is graphically displayed in Fig 3A and B. An initial decrease in hemoglobin levels was identified within 48 hours of the initiation of therapy and continued through the course of treatment. A mean 20% decrease in hematocrits was identified for all patients at all doses. This effect was associated with a modest reticulocytosis (data not shown). IL-11 had no detectable effects on the numbers of WBCs or subsets of WBCs.
Of the 16 patients enrolled on the study, 12 received rhIL-11 at their assigned dose after at least two cycles of chemotherapy.
Hematologic effects of IL-11 a f e r chemotherapy.
The median platelet counts for the first cycle of chemotherapy are shown in Fig 4. Although no patient developed severe thrombocytopenia in the first cycle of chemotherapy (defined as a platelet count <20,OOO/pL), the median nadir platelet counts for patients receiving rhIL-11 at doses 2 2 5 mgkg/d appear to be higher compared with those patients treated at the 10-pg/kg/d dose. Table 5 reports the nadir platelet counts for each patient across the first two cycles of planned chemotherapy. Mean nadir platelet counts of 67, 159, 152, and 161,OOO/pL were seen during the first cycle in the lo-, 25-,50-, and 75-pgkgld dose levels, respectively. This apparent attenuation of thrombocytopenia at doses of 25, 50, and 75 pgkg was also evident during the second cycle of therapy where mean nadir platelet counts of 44,OOO, 140,000, 126,000, and 102,000/yL were seen for the four doses, respectively. Unfortunately, patient drop-out (only 9 patients completed cycle 3 and 7 completed cycle 4) makes the evaluation of IL-11's effects on thrombocytopenia in the latter two cycles difficult. However, there does appear to be a trend toward a continued attenuation of severe thrombocytopenia at doses 2 2 5 pg/kg/d. Platelet transfusions were cycle appeared to be constant during each of the cycles of therapy. Eight patients were transfused with packed red blood cells a total of 1 1 times, with three of these eight patients having two transfusions each.
IL-11 did not ameliorate the leukopenia or neutropenia associated with our moderately dose-intensive chemother- Data not available because patient discontinued particiption in study.
For
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apy. Based on this observation, patients experiencing severe neutropenia (defined as an absolute neutrophil count 4 0 0 cells/pL for >5 days) or an episode of neutropenic fever in cycles 1 or 2 were allowed to receive standard regimens of G-CSF (5 ygkg SC once daily) in cycles 3 and 4. A total of 33 cycles of chemotherapy were administered without G-CSF, whereas seven patients were treated with G-CSF during a total of nine cycles of chemotherapy. During cycles in which G-CSF was not administered, patients experienced a mean of 6.58 5 1.5 days of neutropenia (range, 5 to 10 days) compared with a mean of 2.56 2 1.4 days of neutropenia (range, 0 to 5 days) in cycles during which G-CSF was administered. This result was highly statistically significant (P < .001). This concomitant use of IL-11 and G-CSF was not associated with any additional unexpected adverse events in any of the patients treated.
No significant changes in either renal or hepatic function were seen related to IL-11 therapy. A mean 16.25% reduction in total cholesterol levels was seen comparing baseline levels to nadir values, for all dose levels. Cholesterol nadirs occurred on day 3 of dosing in all patients. These reductions in cholesterol appeared to be related to reduction in both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol. Similar changes were not typically seen in serum higlyceride levels. The effect of IL-ll on cholesterol did not appear to be dose-related and was transient. A non-doserelated mean 18.75% reduction in total serum protein and a mean 27.75% reduction in serum albumin were seen in cycle 0 with nadir values occumng on day 15, 1 day after completion of IL-11 therapy. These changes are believed to possibly be related to the previously noted plasma volume expansion. Effects of IL-11 on acute-phase proteins and coagulation parameters. Subcutaneous administration of IL-1 1 resulted in an increase in acute-phase proteins during all cycles of therapy. Serum levels of C-reactive protein (CRP) increased in response to treatment at all doses studied. Maximal increases occurred within the first week of therapy and remained elevated for the duration of rhIL-11 administration. These increases appeared to be dose-related for doses 2 2 5 ygkg/d and were statistically significant at the two highest dose levels (Fig 5) . After completion of IL-11 dosing, CRP levels returned to baseline before the next cycle of therapy. Mean fibrinogen levels also increased as a result of IL-11 therapy. At the 50-and 75-ygkg dose levels, a statistically significant increase in the mean fibrinogen levels compared with baseline values was seen by day 12 of rhIL-11 therapy. At the 50-ygkg dose level these changes were transient in nature and were no longer significant by day 15. In contrast, patients treated at the 75-ygkg dose maintained this increase through day 19, after which their fibrinogen levels returned to pretreatment values. The increases in both acute-phase proteins similar to that seen in cycle 0 were seen in cycles 1 through 4 when rhIL-I1 was administered after chemotherapy.
The effects of rhIL-11 on coagulation were assessed by showed evidence of a significant effect of rhIL-1 1 therapy on either the PT or PTTs. Platelet aggregometry was performed pretreatment and on day 15 of cycle 0 only. Treatment with rhIL-11 did not induce hyperaggregability in any of the patients studied.
DISCUSSION
Thrombocytopenia caused by the administration of doseintensive chemotherapy has become an increasingly significant problem. The use of G-CSF and GM-CSF to reduce the incidence of febrile neutropenic complications has allowed further dose escalation beyond previous hematologic limitations.".'.' As a result, patients are frequently exposed to doses of chemotherapy that are associated with greater degrees of myelosuppression, especially thrombocytopenia. In addition, the development of cumulative hematologic toxicity resulting in significant degrees of anemia and thrombocytopenia have redefined the ability to deliver planned doses of chemotherapy on schedule. Recent data support the use of erythropoietin to reduce the cumulative toxicity of chemotherapy on erythropoiesis.14 Unfortunately, no hematopoietic growth factor to date has demonstrated the ability to reduce the degree of chemotherapy-induced thrombocytopenia. At the present time, clinicians are limited to the use of platelet transfusions and/or dose reductions to support such patients. Although effective therapy, platelet transfusions are inconvenient, potentially toxic, and associated with the risk of the development of alloimm~nization.'~ We performed a phase I trial of rhIL-11, a new hematopoietic growth factor with preclinical thrombopoietic activity, to evaluate its safety as well as its ability to reduce the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From development of thrombocytopenia in women with breast cancer receiving dose-intensive chemotherapy. Although the maximally tolerated dose was not formally identified (based on the protocol definition of two or more dose-limiting toxicities at a dose level), dose escalation of rhIL-11 was discontinued following the development of the cerebrovascular event in the first patient treated at a dose of 100 ygkgld. This decision was based on the observation that the intensity of the constitutional symptoms observed in patients treated at doses <lo0 pgkg appeared to be increasing in a doserelated manner. While the WHO common toxicity criteria does not quantify constitutional symptoms, subjective interpretation of patient complaints supported this conclusion. At the 75-ygkg dose level, patients found that their constitutional complaints were significant enough so as to limit their ability to carry out their normal daily routines. This was particularly true of the diffuse myalgias and arthralgias that accompanied therapy at this dose level. Based on the decision to halt dose escalation, while not formally defined by the criteria established at the beginning of the study, 75 pg/ kg/d would be identified as the maximally tolerated dose in this phase I trial. However, because of the subjective degree of constitutional complaints by patients at this dose, expansion of the 50-pgkg dose level was undertaken with an additional three patients to further identify the safety of this better tolerated dose level.
The cerebrovascular accident in the patient treated at the 100 ygkg dose was not associated with an IL-11 -induced thrombocytosis nor changes in her PT or F'TT. In addition, a less than twofold elevation of fibrinogen was noted at the time of the event. One additional patient, treated at the 50-pg/kg dose, was removed after the identification of a small intracerebral bleed during a febrile neutropenic episode. She had a long-standing history of hypertension and it was believed that she developed a hypertensive bleed related to her chemotherapy-induced thrombocytopenia and the stress of her infection. Among the remaining 14 patients, only 2, also treated at the 50-ygkg dose level, experienced thrombosis of indwelling central venous access devices. This common complication may be more related to technical aspects of catheter placement in patients with malignancies, a known risk factor for thrombosis. Among the remaining patients no clinical evidence of thrombosis was seen. As noted previously, platelet aggregometry studies were performed at baseline and after 14 days of rhIL-11 therapy in all patients and demonstrated no consistent change in platelet function. Although fibrinogen levels increased in patients treated at all doses, only at the 75-ygkg dose level was a sustained statistically significant increase noted. Evaluations of standard coagulation profiles including PTs and F'TTs similarly showed no evidence consistent with coagulation activation. Additional studies with rhIL-1 1 in normal volunteers has demonstrated findings similar to those noted above. In addition, increases in plasma levels of von Willebrand factor have been seen. 16 These changes in coagulation factors are rapidly reversible on discontinuation of IL-11 and, could potentially be of benefit to patients who are severely thrombocytopenic with regard to preventing serious bleeding complications.
Other than the patient treated at the 100-ygkg dose level noted above, no patient experienced grade 3 or greater doselimiting toxicity related to rhIL-11 administration. The principal adverse events associated with rhIL-1 1 were constitutional symptoms (arthralgias and myalgias), fatigue, and a dependent extremity edema. These effects developed principally in the latter half of the 14 days of rhIL-11 dosing and reversed after the completion of therapy. While at no time dose-limiting, the constitutional side effects were of a greater intensity at doses of 50 pgkg and higher as indicated by the greater percentage of patients with WHO grade 2 adverse events. Patients at the 10-and 25-pgkg doses tolerated therapy exceptionally well with few clinically significant side effects related to rhIL-11. An important observation is that rhIL-11, unlike other hematopoietic growth factors (such as GM-CSF, IL-3, or IL-6), is not associated with fever. This is particularly interesting given the fact that although other agents in the same family as IL-11 (such as IL-6, leukemia inhibitory factor, and ciliary neurotrophic factor) have individual cell surface receptors, their postreceptor signaling pathway, mediated via GP-130, is the same. This suggests that receptor numbers or location may play a role in some of the differences in activity as well as adverse events associated with these agents. Neither capillary leak syndrome nor renal or hepatic dysfunction were identified in any of the patients treated.
Antibody formation was confirmed for one patient. A second patient demonstrated an antibody response that was consistent with antibody formation as a result of product exposure but had insufficient sample to confirm specificity to the rhIL-11 protein. In both cases, the antibody titers were below the level which has previously been characterized as having neutralizing capacity, and hence were not felt to be of clinical significance.
Treatment with rhIL-11 is associated with a therapy-related anemia that is rapid in onset, reversible, and not associated with any evidence of hemolysis or occult blood loss. Although patients in this study were phlebotomized frequently for laboratory studies, this volume was insufficient to account for the degree of anemia seen. Further investigations identified the fact that patients receiving rhIL-I 1 develop a significant expansion of their plasma volume which contributes to the development of a dilutional anemia. Although this may not be the only mechanism involved, it appears from our studies to be the predominant one. Other investigators have reported similar findings regarding the anemia related to IL-11 and IL-6 and have reached a similar conclusion, validating our findings." ''
The hematologic effects of rhIL-11 were assessed independently during the 28-day prechemotherapy safety period termed cycle 0. During this time patients received rhIL-11 at their assigned dose for 14 days followed by 14 days of observation. The administration of rhIL-1 1 was associated with an initial decrease in platelet counts followed by a dose-related increase in platelets with peak platelet counts occurring after the completion of rhIL-11 therapy. A gradual return to pretreatment platelet counts occurred over the ensuing 2 weeks of observation. The initial decrease in platelet count is possibly the result of an early rapid increase in
